ONC

Beone Medicines Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth↑ 9/10
  • Value↓ 1/10
Beone Medicines sales and earnings growth
ONC Growth
Great
  • Revenue Y/Y↑ 37.44%
  • EPS Y/Y↑ 224.14%
  • FCF Y/Y↑ 734.04%
Beone Medicines gross and profit margin trends
ONC Profitability
Good
  • Gross margin ↑ 88.30%
  • EPS margin↓ 8.90%
  • ROIC 5Y↑ -25.55%
Beone Medicines net debt vs free cash flow
ONC Risk
Great
  • Debt / Equity↓ 0.4
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 7.8

Beone Medicines stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks